JP2025094100A5 - - Google Patents
Info
- Publication number
- JP2025094100A5 JP2025094100A5 JP2025044149A JP2025044149A JP2025094100A5 JP 2025094100 A5 JP2025094100 A5 JP 2025094100A5 JP 2025044149 A JP2025044149 A JP 2025044149A JP 2025044149 A JP2025044149 A JP 2025044149A JP 2025094100 A5 JP2025094100 A5 JP 2025094100A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- represents tert
- butyloxycarbonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762536271P | 2017-07-24 | 2017-07-24 | |
| US62/536,271 | 2017-07-24 | ||
| US201762573894P | 2017-10-18 | 2017-10-18 | |
| US62/573,894 | 2017-10-18 | ||
| PCT/US2018/043338 WO2019023147A1 (en) | 2017-07-24 | 2018-07-23 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH NLRP ACTIVITY |
| JP2020503754A JP7412328B2 (ja) | 2017-07-24 | 2018-07-23 | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 |
| JP2023218835A JP7654767B2 (ja) | 2017-07-24 | 2023-12-26 | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023218835A Division JP7654767B2 (ja) | 2017-07-24 | 2023-12-26 | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025094100A JP2025094100A (ja) | 2025-06-24 |
| JP2025094100A5 true JP2025094100A5 (https=) | 2025-10-21 |
| JP7813931B2 JP7813931B2 (ja) | 2026-02-13 |
Family
ID=63143410
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020503754A Active JP7412328B2 (ja) | 2017-07-24 | 2018-07-23 | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 |
| JP2023218835A Active JP7654767B2 (ja) | 2017-07-24 | 2023-12-26 | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 |
| JP2025044149A Active JP7813931B2 (ja) | 2017-07-24 | 2025-03-18 | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020503754A Active JP7412328B2 (ja) | 2017-07-24 | 2018-07-23 | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 |
| JP2023218835A Active JP7654767B2 (ja) | 2017-07-24 | 2023-12-26 | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 |
Country Status (34)
| Country | Link |
|---|---|
| US (4) | US11203579B2 (https=) |
| EP (2) | EP3658539B1 (https=) |
| JP (3) | JP7412328B2 (https=) |
| KR (1) | KR102565167B1 (https=) |
| CN (3) | CN111094243B (https=) |
| AU (1) | AU2018307743C1 (https=) |
| BR (1) | BR112020001476A2 (https=) |
| CA (1) | CA3068836A1 (https=) |
| CL (1) | CL2020000215A1 (https=) |
| CO (1) | CO2020000527A2 (https=) |
| CR (1) | CR20200037A (https=) |
| CU (1) | CU24615B1 (https=) |
| DK (1) | DK3658539T3 (https=) |
| DO (1) | DOP2020000012A (https=) |
| EC (1) | ECSP20005581A (https=) |
| ES (1) | ES2988798T3 (https=) |
| FI (1) | FI3658539T3 (https=) |
| HR (1) | HRP20240521T1 (https=) |
| HU (1) | HUE066566T2 (https=) |
| IL (1) | IL271259B2 (https=) |
| JO (1) | JOP20200011B1 (https=) |
| LT (1) | LT3658539T (https=) |
| MX (1) | MX2020000911A (https=) |
| NZ (1) | NZ761026A (https=) |
| PE (1) | PE20200723A1 (https=) |
| PH (1) | PH12020500127A1 (https=) |
| PL (1) | PL3658539T3 (https=) |
| PT (1) | PT3658539T (https=) |
| RS (1) | RS65492B1 (https=) |
| SA (1) | SA520411125B1 (https=) |
| SG (1) | SG11201912166XA (https=) |
| SI (1) | SI3658539T1 (https=) |
| WO (1) | WO2019023147A1 (https=) |
| ZA (1) | ZA201908154B (https=) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018225018A1 (en) | 2017-06-09 | 2018-12-13 | Cadila Healthcare Limited | Novel substituted sulfoximine compounds |
| ES2988798T3 (es) | 2017-07-24 | 2024-11-21 | Novartis Ag | Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP |
| MA49903A (fr) | 2017-08-15 | 2020-06-24 | Inflazome Ltd | Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3 |
| UY37848A (es) | 2017-08-15 | 2019-03-29 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 |
| EP3668843A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
| EP3692020A1 (en) | 2017-10-03 | 2020-08-12 | Inflazome Limited | Novel compounds |
| KR20240152947A (ko) | 2017-10-18 | 2024-10-22 | 인사이트 코포레이션 | Pi3k-감마 저해제로서의 3차 하이드록시기로 치환된 축합된 이미다졸 유도체 |
| WO2019092171A1 (en) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| CN111315733A (zh) | 2017-11-09 | 2020-06-19 | 英夫拉索姆有限公司 | 新颖磺酰胺甲酰胺化合物 |
| GB201721185D0 (en) | 2017-12-18 | 2018-01-31 | Nodthera Ltd | Sulphonyl urea derivatives |
| US11905252B2 (en) | 2018-03-02 | 2024-02-20 | Inflazome Limited | Compounds |
| AU2019299444A1 (en) * | 2018-07-03 | 2021-01-14 | Novartis Ag | Methods of treating or selecting a treatment for a subject resistant to tnf inhibitor using a NLRP3 antagonist |
| CA3105521A1 (en) * | 2018-07-20 | 2020-01-23 | F. Hoffmann-La Roche Ag | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
| GB201902327D0 (en) | 2019-02-20 | 2019-04-03 | Inflazome Ltd | Novel compounds |
| KR20210053910A (ko) | 2018-08-15 | 2021-05-12 | 인플라좀 리미티드 | 신규한 설폰아마이드유레아 화합물 |
| CR20250050A (es) | 2018-09-05 | 2025-03-19 | Incyte Corp | Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165) |
| ES3042546T3 (en) * | 2018-11-13 | 2025-11-21 | Novartis Ag | Compounds and compositions for treating conditions associated with nlrp activity |
| EP3880673B1 (en) | 2018-11-13 | 2024-01-03 | Novartis AG | Compounds and compositions for treating conditions associated with nlrp activity |
| US12134611B2 (en) | 2018-11-13 | 2024-11-05 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| WO2020102576A1 (en) * | 2018-11-16 | 2020-05-22 | Novartis Inflammasome Research, Inc. | Compounds and compositions for treating conditions associated with nlrp activity |
| GB201819083D0 (en) | 2018-11-23 | 2019-01-09 | Inflazome Ltd | Novel compounds |
| EA202191968A1 (ru) | 2019-01-14 | 2021-11-16 | Кадила Хелзкэр Лимитед | Новые замещенные производные сульфонилмочевины |
| EP3914585A1 (en) * | 2019-01-23 | 2021-12-01 | Novartis AG | Sulfonimidamide compounds and compositions for treating conditions associated with nlrp activity |
| GB201905265D0 (en) | 2019-04-12 | 2019-05-29 | Inflazome Ltd | Inflammasome inhibition |
| GB201908219D0 (en) | 2019-06-10 | 2019-07-24 | Axalbion Sa | Therapeutic use of a compound |
| PL3983387T3 (pl) | 2019-06-12 | 2024-08-19 | NodThera Limited | Pochodne sulfonylomocznika i ich zastosowania |
| EP3986879B1 (en) | 2019-06-21 | 2024-10-02 | AC Immune SA | Fused 1,2-thiazoles and 1,2-thiazines which act as nlrp3 modulators |
| WO2021002887A1 (en) | 2019-07-02 | 2021-01-07 | Novartis Inflammasome Research, Inc. | Gut-targeted nlrp3 antagonists and their use in therapy |
| CN110590576A (zh) * | 2019-08-15 | 2019-12-20 | 安徽金禾实业股份有限公司 | 一种4-多氟代甲氧基邻苯二胺的制备方法 |
| JP2022545400A (ja) | 2019-08-16 | 2022-10-27 | インフレイゾーム リミテッド | Ｎｌｒｐ３阻害剤として有用な大環状スルホニル尿素誘導体 |
| WO2021032588A1 (en) | 2019-08-16 | 2021-02-25 | Inflazome Limited | Macrocyclic sulfonylamide derivatives useful as nlrp3 inhibitors |
| US20220289692A1 (en) | 2019-09-06 | 2022-09-15 | Inflazome Limited | Nlrp3 inhibitors |
| JP7392169B2 (ja) * | 2019-11-12 | 2023-12-05 | 成都百裕制薬股▲ふん▼有限公司 | アミド誘導体及びその調製方法並びに医薬における応用 |
| KR102333562B1 (ko) * | 2019-12-03 | 2021-12-01 | 전남대학교 산학협력단 | Nlrp3 인플라마좀 억제제를 포함하는 노인성 치주질환 예방, 개선 또는 치료용 조성물 및 그의 방법 |
| PH12022551767A1 (en) * | 2020-01-22 | 2023-11-29 | Hoffmann La Roche | Sulfonimidamide compounds as nlrp3 modulators |
| WO2021165245A1 (en) | 2020-02-18 | 2021-08-26 | Inflazome Limited | Compounds |
| US12428391B2 (en) | 2020-06-11 | 2025-09-30 | Cisen Pharmaceutical Co., Ltd | Dimethylsulfoximine derivative |
| AU2021291065B2 (en) | 2020-06-19 | 2025-06-26 | Ac Immune Sa | Dihydrooxazole and thiourea or urea derivatives modulating the nlrp3 inflammasome pathway |
| WO2022023907A1 (en) | 2020-07-31 | 2022-02-03 | Novartis Ag | Methods of selecting and treating patients at elevated risk of major adverse cardiac events |
| IL301055A (en) | 2020-09-04 | 2023-05-01 | Nodthera Ltd | Sulphamoyl urea derivatives containing alkyl-oxacycloalkyl moiety and uses thereof |
| KR102409344B1 (ko) * | 2020-09-22 | 2022-06-15 | 가톨릭대학교 산학협력단 | Nlrp3 인플라마좀 억제제 및 이의 용도 |
| KR102409345B1 (ko) * | 2020-09-22 | 2022-06-16 | 가톨릭대학교 산학협력단 | Nlrp3 인플라마좀 억제제 및 이의 용도 |
| CN116507608A (zh) * | 2020-11-20 | 2023-07-28 | 戴纳立制药公司 | 化合物、组合物和方法 |
| US20240010639A1 (en) | 2020-11-20 | 2024-01-11 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Triazine dione derivative, preparation method therefor and application thereof in medicine |
| CN113061111A (zh) * | 2021-03-16 | 2021-07-02 | 无锡海伦生物科技有限公司 | 具有光交联活性的氨基酸类化合物的制备方法 |
| US11932630B2 (en) | 2021-04-16 | 2024-03-19 | Novartis Ag | Heteroaryl aminopropanol derivatives |
| CN116635374B (zh) * | 2021-05-10 | 2025-05-06 | 康百达（四川）生物医药科技有限公司 | 酰胺衍生物及其应用 |
| CN116917282A (zh) * | 2021-05-10 | 2023-10-20 | 成都百裕制药股份有限公司 | 酰胺衍生物及其应用 |
| CN116635373A (zh) * | 2021-05-10 | 2023-08-22 | 成都百裕制药股份有限公司 | 酰胺衍生物及其应用 |
| CN115616216B (zh) * | 2021-07-15 | 2025-08-12 | 华南理工大学 | 抑制或阻断faah与nlrp3之间相互作用的制剂的用途 |
| US20250082611A1 (en) | 2021-07-23 | 2025-03-13 | Novartis Ag | Dosing regimen for an nlrp3 inhibitor in the treatment of osteoarthritis |
| CN118302415A (zh) * | 2021-12-03 | 2024-07-05 | 辰欣药业股份有限公司 | 二甲基亚磺酰亚胺衍生物的制备方法 |
| WO2023098612A1 (zh) * | 2021-12-03 | 2023-06-08 | 南京明德新药研发有限公司 | 二甲基亚磺酰亚胺衍生物的盐型及晶型 |
| CN118541366A (zh) | 2021-12-22 | 2024-08-23 | Ac免疫有限公司 | 二氢噁唑衍生物化合物 |
| CN114436851B (zh) * | 2022-01-17 | 2023-08-22 | 常州大学 | 一种n,n-二甲基苄胺及其衍生物的制备方法 |
| CN114989058B (zh) * | 2022-06-02 | 2024-04-16 | 中国科学院成都生物研究所 | 一种手性氯代砜亚胺类化合物及其衍生物的制备方法 |
| EP4554945A1 (en) | 2022-07-14 | 2025-05-21 | AC Immune SA | Pyrrolotriazine and imidazotriazine derivatives as modulators of the nlrp3 inflammasome pathway |
| CN115227712A (zh) * | 2022-07-26 | 2022-10-25 | 上海市第五人民医院 | NaHS在制备治疗骨质疏松药物中的应用 |
| EP4561574A1 (en) | 2022-07-27 | 2025-06-04 | Novartis AG | Dosing regimen for a nlrp3 inhibitor |
| AU2023313032A1 (en) | 2022-07-28 | 2025-01-23 | Ac Immune Sa | Novel compounds |
| AU2024280075A1 (en) | 2023-06-02 | 2025-12-11 | Merck Sharp & Dohme Llc | 5,6-Unsaturated Bicyclic Heterocycles Useful as Inhibitors of Nod-Like Receptor Protein 3 |
| WO2025068958A1 (en) | 2023-09-29 | 2025-04-03 | Novartis Ag | Nlrp3 inhibitor for use in lowering the risk of cardiovascular diseases |
| WO2025133307A1 (en) | 2023-12-22 | 2025-06-26 | Ac Immune Sa | Heterocyclic modulators of the nlrp3 inflammasome pathway |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
| WO2025153625A1 (en) | 2024-01-17 | 2025-07-24 | Ac Immune Sa | Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway |
| WO2025153624A1 (en) | 2024-01-17 | 2025-07-24 | Ac Immune Sa | Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway |
| WO2025163069A1 (en) | 2024-01-31 | 2025-08-07 | Ac Immune Sa | Novel compounds |
| WO2026057747A1 (en) | 2024-09-11 | 2026-03-19 | Ac Immune Sa | Therapeutic use of nlrp3 inflammasome pathway inhibitor compounds |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4666506A (en) | 1984-08-08 | 1987-05-19 | E. I. Du Pont De Nemours And Company | Herbicidal pyrimidines |
| ZA929699B (en) * | 1991-12-20 | 1994-06-14 | Lilly Co Eli | Sulfonimidamides |
| US5258406A (en) | 1991-12-20 | 1993-11-02 | Eli Lilly And Company | Sulfonimidamides |
| US5169860A (en) | 1992-03-13 | 1992-12-08 | Eli Lilly And Company | Antitumor compositions and methods of treatment |
| PT1270565E (pt) | 1997-01-29 | 2004-09-30 | Pfizer | Furano-2-sulfonamida 4-substituida e sua utilizacao na preparacao de derivados de sulfonilureia |
| EP1214087A1 (en) | 1999-09-14 | 2002-06-19 | Pfizer Products Inc. | Combination treatment with il-1ra and compounds that inhibit il-1 processing and release |
| US6906063B2 (en) * | 2000-02-04 | 2005-06-14 | Portola Pharmaceuticals, Inc. | Platelet ADP receptor inhibitors |
| CA2369967A1 (en) | 2001-02-12 | 2002-08-12 | Joseph Anthony Cornicelli | Methods of treating nuclear factor-kappa b mediated diseases and disorders |
| BRPI1006380B1 (pt) | 2009-04-16 | 2021-04-06 | Koninklijke Philips N.V. | Método para comunicação em uma rede de uma primeira estação a uma segunda estação e estação de rádio |
| TW201439066A (zh) * | 2012-11-30 | 2014-10-16 | Kyowa Hakko Kirin Co Ltd | 含氮雜環化合物 |
| SI3259253T1 (sl) | 2015-02-16 | 2020-07-31 | The University Of Queensland | Sulfonilsečnine in sorodne spojine ter njihova uporaba |
| EP3436432B1 (en) | 2016-03-30 | 2021-01-27 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
| US11339136B2 (en) * | 2016-04-18 | 2022-05-24 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| US11447460B2 (en) * | 2016-04-18 | 2022-09-20 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| CA3021349A1 (en) | 2016-04-19 | 2017-10-26 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
| EP3571187B1 (en) | 2017-01-23 | 2023-11-22 | Genentech, Inc. | Chemical compounds as inhibitors of interleukin-1 activity |
| TWI674261B (zh) | 2017-02-17 | 2019-10-11 | 美商英能腫瘤免疫股份有限公司 | Nlrp3 調節劑 |
| WO2018225018A1 (en) | 2017-06-09 | 2018-12-13 | Cadila Healthcare Limited | Novel substituted sulfoximine compounds |
| NZ760129A (en) | 2017-07-07 | 2025-12-19 | Inflazome Ltd | Novel sulfonamide carboxamide compounds |
| ES2988798T3 (es) * | 2017-07-24 | 2024-11-21 | Novartis Ag | Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP |
| JP7349981B2 (ja) | 2017-07-24 | 2023-09-25 | ノバルティス アーゲー | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 |
| EP3668840A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| EP3692020A1 (en) * | 2017-10-03 | 2020-08-12 | Inflazome Limited | Novel compounds |
| CA3105521A1 (en) | 2018-07-20 | 2020-01-23 | F. Hoffmann-La Roche Ag | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
| GB201902327D0 (en) | 2019-02-20 | 2019-04-03 | Inflazome Ltd | Novel compounds |
| BR112021003665A2 (pt) | 2018-09-13 | 2021-05-18 | Bayer Aktiengesellschaft | derivados de heterocicleno como agentes de controle de pragas |
| EP3911323A4 (en) | 2019-01-18 | 2022-11-16 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS |
-
2018
- 2018-07-23 ES ES18752376T patent/ES2988798T3/es active Active
- 2018-07-23 US US16/632,849 patent/US11203579B2/en active Active
- 2018-07-23 CA CA3068836A patent/CA3068836A1/en active Pending
- 2018-07-23 FI FIEP18752376.6T patent/FI3658539T3/fi active
- 2018-07-23 CN CN201880050915.XA patent/CN111094243B/zh active Active
- 2018-07-23 JP JP2020503754A patent/JP7412328B2/ja active Active
- 2018-07-23 CN CN202310765173.1A patent/CN117143042A/zh active Pending
- 2018-07-23 EP EP18752376.6A patent/EP3658539B1/en active Active
- 2018-07-23 CR CR20200037A patent/CR20200037A/es unknown
- 2018-07-23 WO PCT/US2018/043338 patent/WO2019023147A1/en not_active Ceased
- 2018-07-23 HU HUE18752376A patent/HUE066566T2/hu unknown
- 2018-07-23 PL PL18752376.6T patent/PL3658539T3/pl unknown
- 2018-07-23 AU AU2018307743A patent/AU2018307743C1/en active Active
- 2018-07-23 CU CU2020000004A patent/CU24615B1/es unknown
- 2018-07-23 CN CN202311185119.6A patent/CN117209447A/zh active Pending
- 2018-07-23 KR KR1020207004803A patent/KR102565167B1/ko active Active
- 2018-07-23 NZ NZ761026A patent/NZ761026A/en unknown
- 2018-07-23 IL IL271259A patent/IL271259B2/en unknown
- 2018-07-23 EP EP24151235.9A patent/EP4349820A3/en active Pending
- 2018-07-23 DK DK18752376.6T patent/DK3658539T3/da active
- 2018-07-23 LT LTEPPCT/US2018/043338T patent/LT3658539T/lt unknown
- 2018-07-23 PT PT187523766T patent/PT3658539T/pt unknown
- 2018-07-23 SI SI201831090T patent/SI3658539T1/sl unknown
- 2018-07-23 BR BR112020001476-1A patent/BR112020001476A2/pt unknown
- 2018-07-23 MX MX2020000911A patent/MX2020000911A/es unknown
- 2018-07-23 PE PE2020000150A patent/PE20200723A1/es unknown
- 2018-07-23 HR HRP20240521TT patent/HRP20240521T1/hr unknown
- 2018-07-23 SG SG11201912166XA patent/SG11201912166XA/en unknown
- 2018-07-23 RS RS20240513A patent/RS65492B1/sr unknown
-
2019
- 2019-09-16 US US16/572,528 patent/US10654816B2/en active Active
- 2019-12-09 ZA ZA2019/08154A patent/ZA201908154B/en unknown
-
2020
- 2020-01-17 PH PH12020500127A patent/PH12020500127A1/en unknown
- 2020-01-17 CO CONC2020/0000527A patent/CO2020000527A2/es unknown
- 2020-01-23 SA SA520411125A patent/SA520411125B1/ar unknown
- 2020-01-23 DO DO2020000012A patent/DOP2020000012A/es unknown
- 2020-01-24 CL CL2020000215A patent/CL2020000215A1/es unknown
- 2020-01-24 EC ECSENADI20205581A patent/ECSP20005581A/es unknown
- 2020-01-26 JO JOJO/P/2020/0011A patent/JOP20200011B1/ar active
-
2021
- 2021-10-07 US US17/496,375 patent/US11724992B2/en active Active
-
2023
- 2023-05-18 US US18/319,630 patent/US12084424B2/en active Active
- 2023-12-26 JP JP2023218835A patent/JP7654767B2/ja active Active
-
2025
- 2025-03-18 JP JP2025044149A patent/JP7813931B2/ja active Active